CD274 and neoplasm: Therefore, to evaluate the synergistic therapeutic effects of combined P21 and anti-PD-L1 therapy, each drug was injected into the CT26.CL25 tumor-bearing mouse model according to the schedule presented in Figure 4A (0.78 mg/kg P21 and 10 mg/kg anti-PD-L1).